People who inject drugs represent the core of the hepatitis C virus (HCV) epidemic worldwide. There are compelling data demonstrating that with the appropriate programmes, treatment for HCV infection among PWID is successful. The approaching era of interferon-free directly acting antiviral therapy has the potential to provide one of the great advances of clinical medicine.
Simple, tolerable and highly effective therapy will likely enhance the numbers of PWID cured of HCV infection. This presentation reviews evidence to argue that we should strive for the eradication of HCV infection among PWID, considers how feasible this is, and what elements of intervention strategy are needed to bring this about.
For information about this seminar, please contact: Rachael Parker (Rachael.email@example.com)
Admission: Free and open to all with no ticket required. Entry is on a first come, first served basis.
Please, click here for more details about the location and the event.
Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.